Chief Executive Officer · AVENUE THERAPEUTICS, INC. (ATXI)

Alexandra MacLean

A named executive officer of AVENUE THERAPEUTICS in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$447,307

Salary $420,000Stock awards $13,307

FY2024: $840,100

1st of 2 named executive officers at Avenue Therapeutics by FY2025 total.

2 named officers on file for AVENUE THERAPEUTICS, FY2025

Alexandra MacLean’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how AVENUE THERAPEUTICS’s whole pay program stands against its peers

  • AVENUE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ATXI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 30, 2026 (10-K).

Free

Get Alexandra MacLean’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Alexandra MacLean compensation by year

AVENUE THERAPEUTICS Summary Compensation Table · all 4 fiscal years held
In US dollars, as AVENUE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$153,585$400,000$420,000$420,000
Bonus$120,000$0$0$0
Stock awards—$0$406,300$13,307
Option awards—$800,000$0$0
Non-equity incentive$20,000$0$0$0
Pension and deferred compensation—$0$0$0
All other$6,958$13,200$13,800$14,000
Total$280,542$1,213,200$840,100$447,307

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AVENUE THERAPEUTICS, INC. 10-K filed March 30, 2026, accession 0001437749-26-010359, and prior-year filings. Open the filing on EDGAR.

How this page was built: the AVENUE THERAPEUTICS, INC. filed document, accession 0001437749-26-010359. Every figure is read from that document and cited to the page and table it appears in. Filed March 30, 2026.

$281K
$1.2M
$840K
$447K
FY22
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU42,500$28,909—
Option2,664—$85.50

Per the Outstanding Equity Awards at Fiscal Year-End table in AVENUE THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

AVENUE THERAPEUTICS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Alexandra MacLean · this pageChief Executive Officer$447,307
David JinInterim Chief Financial Officer and Chief Operating Officer$7,984

Board service

AVENUE THERAPEUTICS board · FY2024

How this board is paid

Company policy: AVENUE THERAPEUTICS pays directors a $50,000 cash retainer. As stated in AVENUE THERAPEUTICS's FY2024 proxy.

The full AVENUE THERAPEUTICS compensation record

free company brief

This page is one person within AVENUE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AVENUE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alexandra MacLean's compensation dossier · One-time report. No refunds.